Daniel DeAngelo, MD, PhD Discusses Acute Myeloid Leukemia
Daniel DeAngelo, MD, PhD
At the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Rare Disease Report sat down with Daniel DeAngelo, MD, PhD of the Dana Farber Cancer Institute to discuss acute myeloid leukemia (AML), his two studies evaluating both elderly and relapsed/refractory patients, and the potential treatment option GMI-1271.
Among the questions asked were:
What is GMI-1271? (0:01)
What conclusions came of the trial involving GMI-1271 in elderly AML patients? (0:31)
Are elderly AML patients more difficult to treat than younger patients? (1:35)
What other studies have been conducted to satisfy the unmet needs of AML patients? (2:41)